Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Study Details
Study Description
Brief Summary
The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary.
The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed.
Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Outcome Measures
Primary Outcome Measures
- Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact. [Baseline to date of death from any cause (Jan 1- 2009-June 30-2020)]
Overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Female and male patients diagnosed with chronic myeloid leukemia
-
Patients receiving tyrosine kinase inhibitor therapy under the terms of the current marketing authorization
Exclusion Criteria:
- Patients receiving TKI for non-CML diagnoses
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Pfizer | Budapest | Hungary |
Sponsors and Collaborators
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- B1871064